An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients
Clinical trial NCT06923891 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06923891
- Sponsor
- Vanguard Research Group
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-16
- Primary completion
- 2026-10-30
- Enrollment
- 172
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.